Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

QUEST DIAGNOSTICS INCORPORATED

(DGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Quest Diagnostics Incorporated : Mizuho Securities Adjusts Quest Diagnostics PT to $149 From $158, Maintains Buy Rating

06/07/2021 | 12:24pm EDT


© MT Newswires 2021
All news about QUEST DIAGNOSTICS INCORPORATED
07/23QUEST DIAGNOSTICS INCORPORATED : INC Management's Discussion and Analysis of Fin..
AQ
07/23QUEST DIAGNOSTICS INCORPORATED : Baird Adjusts Quest Diagnostics' Price Target t..
MT
07/23QUEST DIAGNOSTICS INCORPORATED : UBS Adjusts Quest Diagnostics' Price Target to ..
MT
07/22Quest Diagnostics to Seek M&A
CI
07/22QUEST DIAGNOSTICS INCORPORATED : Q2 Adjusted Earnings, Revenue Rise; Issues Full..
MT
07/22QUEST DIAGNOSTICS INCORPORATED : Reports Second Quarter 2021 Financial Results; ..
PU
07/22QUEST DIAGNOSTICS : Q2 Earnings Snapshot
AQ
07/22QUEST DIAGNOSTICS INC : Results of Operations and Financial Condition, Financial..
AQ
07/22GUIDANCE : (DGX) QUEST DIAGNOSTICS Sees Fiscal Year 2021 Revenue Range $9.5B - $..
MT
07/22GUIDANCE : (DGX) QUEST DIAGNOSTICS Expects Fiscal Year 2021 EPS Range $10.65 - $..
MT
More news
Financials (USD)
Sales 2021 9 702 M - -
Net income 2021 1 491 M - -
Net Debt 2021 3 488 M - -
P/E ratio 2021 12,3x
Yield 2021 1,69%
Capitalization 17 325 M 17 325 M -
EV / Sales 2021 2,15x
EV / Sales 2022 2,38x
Nbr of Employees 44 500
Free-Float 53,9%
Chart QUEST DIAGNOSTICS INCORPORATED
Duration : Period :
Quest Diagnostics Incorporated Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUEST DIAGNOSTICS INCORPORATED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 141,80 $
Average target price 146,00 $
Spread / Average Target 2,96%
EPS Revisions
Managers and Directors
Stephen H. Rusckowski Chairman, President & Chief Executive Officer
Mark J. Guinan Chief Financial Officer & Executive Vice President
Jay G. Wohlgemuth Chief Medical Officer, Senior VP-R&D, Medical
Gabrielle Wolfson SVP, Chief Information & Digital Officer
Michael E. Prevoznik General Counsel, Senior VP-Legal & Compliance